Virios therapeutics announces termination of at-the-market sales agreement

Atlanta, sept. 18, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and long-covid, today announced that it provided notice of termination of the capital on demand™ sales agreement entered into between the company and jonestrading institutional services llc on july 14, 2023 (the “sales agreement”). the company has initiated the 10-day termination process under the sales agreement, with the official termination taking effect on september 28, 2023. the company will make no sales under the sales agreement during this period.
VIRI Ratings Summary
VIRI Quant Ranking